Objective: To detect the hypermethylation status of RASSF1A promoter in serum DNA of non-small cell lung cancer (NSCLC) patient and evaluate its correlation with clinicopathological parameters.
Methods: Serum DNA was extracted from the peripheral blood of 75 NSCLC patients and another 35 patients with benign pulmonary disease and 15 healthy donors. The methylation status of RASSF1A promoter was determined using methylation-specific PCR (MSP), and the correlation of methylation profiles with clinicopathological parameters was statistically analyzed.
Results: Aberrant methylation of RASSF1A was detected in 23 of 75 (30.7%) cancer patients, but in none of patients with benign pulmonary disease or in healthy donors (P <0.001). RASSF1A hypermethylation status was found to be correlated with late stage and poor differentiation (P < 0.05), but not with gender, age or histopathology in NSCLC patients.
Conclusion: Hypermethylated RASSF1A promoter is frequently found in the serum DNA of non-small cell lung cancer patient, and RASSF1A may become a promising novel biomarker for diagnosis and prognosis prediction in lung cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Mutations in tumor suppressor genes Vhl and Rassf1a cause DNA damage, chromosomal instability and induce gene expression changes characteristic of clear cell renal cell carcinoma.
Kidney Int
December 2024
Clinic of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Comprehensive Cancer Center Freiburg (CCCF), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site, Freiburg; Signalling Research Centres BIOSS and CIBSS, Faculty of Biology University of Freiburg, Freiburg, Germany. Electronic address:
RASSF1A is frequently biallelically inactivated in clear cell renal cell carcinoma (ccRCC) due to loss of chromosome 3p and promoter hypermethylation. Here we investigated the cellular and molecular consequences of single and combined deletion of the Rassf1a and Vhl tumor suppressor genes to model the common ccRCC genotype of combined loss of function of RASSF1A and VHL. In mouse embryonic fibroblasts and in primary kidney epithelial cells, double deletion of Rassf1a and Vhl caused chromosomal segregation defects and increased formation of micronuclei, demonstrating that pVHL and RASSF1A function to maintain genomic integrity.
View Article and Find Full Text PDFAberrant promoter methylation, expression and function of RASSF1A gene in a series of Italian parathyroid tumors.
Endocrine
November 2024
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
Article Synopsis
- Aberrant epigenetic changes, specifically in DNA methylation and non-coding RNAs, play a significant role in the development of parathyroid tumors, particularly concerning the genes RASSF1A and APC, which are often downregulated in cancers.
- In a study of parathyroid adenomas and carcinomas, RASSF1A promoter methylation was found in approximately 90% of adenomas and was inversely related to tumor size; however, APC methylation appeared less frequently.
- The research concluded that the methylation of RASSF1A and APC is a common feature in parathyroid tumors, with the activity of DNA methyltransferases affecting
Minimally Invasive and Emerging Diagnostic Approaches in Endometrial Cancer: Epigenetic Insights and the Promise of DNA Methylation.
Diagnostics (Basel)
November 2024
Consorzio Sannio Tech, 82030 Apollosa, Italy.
Endometrial cancer (EC) is the most common gynecological malignancy, with rising incidence and mortality rates. Key risk factors, including obesity, prolonged estrogen exposure, and metabolic disorders, underscore the urgent need for non-invasive, early diagnostic tools. This review focuses on the role of DNA methylation as a potential biomarker for early EC detection.
View Article and Find Full Text PDFNovel strategy for activating gene expression through triplex DNA formation targeting epigenetically suppressed genes.
RSC Chem Biol
August 2024
Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University 1-1-1 Tsushima-naka Kita-ku Okayama 700-8530 Japan
Article Synopsis
- Triplex DNA formation is a promising technique for targeting genes, but has limitations in its original forming sequences.
- Researchers developed a new molecule, guanidino-dN, which effectively recognizes methylated CG base pairs, allowing for enhanced triplex DNA formation.
- This method successfully increased the expression of the RASSF1A gene in breast cancer cells, leading to suppressed cell growth and changes in gene expression related to cancer survival and apoptosis.
Hypermethylation of genes on chromosome 3p as a biomarker for nasopharyngeal carcinoma diagnosis: A Vietnamese case-control study.
Int J Biol Markers
September 2024
Faculty of Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, Viet Nam.
Background: The crucial event driving nasopharyngeal tumorigenesis is the hypermethylation of chromosome 3p-located tumor suppressor genes. This case-control study aims to investigate the methylation characteristics of , and to potentially develop effective diagnostic biomarkers for nasopharyngeal carcinoma, either individually or in combination.
Methods: The methylation of , , , and in the collection of 93 biopsy samples and 100 healthy swab specimens were evaluated by Nested methylation-specific polymerase chain reaction.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!